Aiosyn

Aiosyn is a medical software company that develops precision pathology solutions integrating deep learning algorithms into existing clinical workflows. These AI-powered algorithms assist pathologists in making accurate and efficient diagnostic decisions, ultimately improving patient outcomes worldwide. The company's core offering revolves around developing and certifying deep learning software for cancer and kidney diseases, enabling pathologists to streamline image analysis tasks with data-driven insights.

Aiosyn's technology, originating from the Computational Pathology Group at Radboud University Medical Center, utilizes neural networks to identify abnormal tissue patterns like cancer with high accuracy. The algorithms are tightly integrated within digital pathology workflows, ensuring a seamless experience for pathologists. Aiosyn collaborates closely with industry and clinical partners to facilitate the adoption of its AI solutions in pathology labs globally.

In June 2023, Aiosyn released its Mitosis Research algorithm, designed to automatically detect and highlight cells undergoing division in whole slide images from cancer biopsies and resections. This innovative tool enhances the efficiency and consistency of mitosis analysis, a critical biomarker for tumor growth evaluation in research settings. Additionally, the company is validating another product, Aiosyn Mitosis Breast, for clinical diagnostics in breast cancer.